| Bioactivity | cis-ACCP is an orally active antimetastatic matrix metalloproteinase-2 (MMP-2) selective inhibitor. cis-ACCP can inhibit MMP-2 and MMP-9 with IC50 values of 4 μM and 20 μM, respectively. cis-ACCP can be used for the research of a variety of chronic diseases[1]. |
| Invitro | cis-ACCP 可以抑制 MMP-2 和 MMP-9，IC50 值分别为 4 μM 和 20 μM[1]。 |
| In Vivo | cis-ACCP（i.p.；50、250、500 mg/kg；每天一次，持续两周）没有显示出毒性作用并减少小鼠转移形成[1]。cis-ACCP（口服，i.v.，i.p.；50、150 mg/kg）仅分布在细胞外液中[1]。 Animal Model: |
| Name | cis-ACCP |
| CAS | 777075-44-2 |
| Formula | C7H15N2O4P |
| Molar Mass | 222.18 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hoffman, Amnon et al. Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. Journal of medicinal chemistry vol. 51,5 (2008): 1406-14. |